HB2049, titled the Access to Family Building Act, would create a federal statutory right to access assisted reproductive technology (ART), including fertility treatments and related medical care. The bill protects a patient’s ability to start, continue, or complete ART treatment, and it also protects the rights of health care providers to perform or assist with ART and to provide evidence-based information, counseling, referrals, and related services. It further recognizes a right for health insurance providers to cover ART treatments or procedures, though it does not require coverage.
The bill defines ART broadly by reference to existing federal law and applies to a wide range of providers, patients, and reproductive genetic materials, including gametes. It authorizes the Attorney General, affected individuals, and providers to bring civil actions against state or local governments, officials, or other entities that impose restrictions that prohibit, unreasonably limit, or interfere with ART access. Courts could award injunctive relief, costs, and attorney’s fees, and federal courts would have jurisdiction without requiring exhaustion of administrative remedies.
HB2049 would significantly preempt conflicting state and local laws by superseding any law, rule, regulation, or standard that conflicts with the Act, including state laws adopted before or after enactment. The bill also states that it overrides the Religious Freedom Restoration Act for purposes of conflict with the Act, while preserving state health and safety regulations that are genuinely necessary and not replaceable by less restrictive alternatives. It expressly says it does not alter state insurance-coverage laws for ART, even though it recognizes a right for insurers to cover such services.
The overall sentiment reflected by the bill’s sponsorship is supportive of expanding and protecting access to fertility care and family-building services. Because there were no committee transcripts or recorded votes provided, there is no documented debate in the supplied materials, but the structure of the bill suggests it is intended to prevent state-level restrictions on fertility treatment and to shield patients and providers from interference. The main likely point of contention is federal preemption: the bill would limit state authority over ART regulation, including potentially laws tied to licensing, medical practice standards, and religious objections, while still preserving some health and safety regulation.
The bill would add a new federal cause of action and statutory protections for access to assisted reproductive technology, affecting patients, fertility clinics, physicians, nurses, pharmacists, insurers, and state and local governments. It would preempt conflicting state and local laws and could be used affirmatively or defensively in federal court to challenge restrictions on ART access. It also directs the Secretary of Health and Human Services to issue implementing regulations within one year.
The bill’s stated purpose and sponsorship indicate strong support for fertility access and family-building rights. No votes or committee debate were provided, so there is no recorded opposition in the supplied materials, but the bill’s broad protections and express preemption language suggest it is designed to be protective of patients and providers and to limit state interference. The general tone is pro-access and pro-treatment continuity.
The most notable contention is the bill’s broad federal override of state law, including its application to laws, rules, and standards that conflict with the Act and its express statement that it applies notwithstanding RFRA. Opponents could object that it reduces state control over medical licensing, regulation of fertility services, and conscience-based or religiously motivated restrictions. Supporters are likely to emphasize that the bill preserves bona fide health and safety regulations and does not change state insurance-coverage mandates, but the scope of preemption remains the central issue.